FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2970959547> ?p ?o ?g. }

• W2970959547 abstract "Use of biologics has been widely advocated for inflammatory diseases recently. Anti-tumor necrosis factor (TNF)-α antibody therapy is reportedly effective against ocular inflammation. However, side effects of TNF-α inhibition have been reported, particularly in the form of exacerbation of infections such as tuberculosis. Paradoxical reactions such as exacerbated inflammation are also well known. Around 20 million humans are infected with human T-cell leukemia virus type 1 (HTLV-1) globally, and this virus can cause adult T-cell leukemia, HTLV-1-associated myelopathy and HTLV-1 uveitis. As for ophthalmic concerns, it has not been identified whether anti-TNF-α antibody stimulates HTLV-1 infected cells and ocular cells to induce HTLV-1 uveitis in HTLV-1 carriers. Here we investigated the effects of anti-TNF-α antibody on ocular status under HTLV-1 infectious conditions using ocular cells and HTLV-1-infected cells in vitro. We used the ARPE-19 human retinal pigment epithelial cell line as ocular cells considered to play an important role in the blood-ocular barrier, and the MT2 HTLV-1-infected cell line. Jurkat cells were used as controls. Infliximab (IFX) was used as an anti-TNF-α antibody to achieve TNF-α inhibition. We evaluated the production of inflammatory cytokines and intercellular adhesion molecule (ICAM)-1, proliferation of ARPE-19, expression of TNF-α receptor (TNF-R) and HTLV-1 proviral DNA, and the percentage of apoptotic ARPE-19. Inflammatory cytokines such as interleukin (IL)-6, IL-8, TNF and ICAM-1 were significantly elevated through contact between ARPE-19 and MT2. Treatment with IFX tented to inhibit TNF production, although the level of production was low, but changes in IL-6, IL-8 and ICAM-1 remained unaffected. Expression of TNFR was unaltered by IFX treatment. HTLV-1 proviral DNA was not significantly changed with treatment. No change in cell growth rate or apoptotic rate of ARPE-19 were seen with the addition of IFX. In conclusion, IFX did not exacerbate production of inflammatory cytokines, and did not affect expression of TNFR, proliferation of ARPE-19, HTLV-1 proviral load or apoptosis of ARPE-19. These results suggest that IFX does not exacerbate HTLV-1-related inflammation in the eye and represents an acceptable treatment option under HTLV-1 infectious conditions." @default.
• W2970959547 created "2019-09-05" @default.
• W2970959547 creator A5013580236 @default.
• W2970959547 creator A5041661834 @default.
• W2970959547 creator A5042940760 @default.
• W2970959547 creator A5043555116 @default.
• W2970959547 creator A5073933688 @default.
• W2970959547 creator A5085316302 @default.
• W2970959547 date "2019-09-18" @default.
• W2970959547 modified "2023-09-26" @default.
• W2970959547 title "Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious Conditions in vitro" @default.
• W2970959547 cites W1538699721 @default.
• W2970959547 cites W1566301867 @default.
• W2970959547 cites W1965448804 @default.
• W2970959547 cites W1974645541 @default.
• W2970959547 cites W1991941671 @default.
• W2970959547 cites W1997134325 @default.
• W2970959547 cites W2001845497 @default.
• W2970959547 cites W2010229835 @default.
• W2970959547 cites W2016031883 @default.
• W2970959547 cites W2016304887 @default.
• W2970959547 cites W2018410379 @default.
• W2970959547 cites W2039301421 @default.
• W2970959547 cites W2045476196 @default.
• W2970959547 cites W2047220417 @default.
• W2970959547 cites W2050079324 @default.
• W2970959547 cites W2050845608 @default.
• W2970959547 cites W2057847545 @default.
• W2970959547 cites W2059000778 @default.
• W2970959547 cites W2073394782 @default.
• W2970959547 cites W2089006005 @default.
• W2970959547 cites W2091442391 @default.
• W2970959547 cites W2092407276 @default.
• W2970959547 cites W2097543258 @default.
• W2970959547 cites W2114081005 @default.
• W2970959547 cites W2144812106 @default.
• W2970959547 cites W2154069579 @default.
• W2970959547 cites W2156351184 @default.
• W2970959547 cites W2164208359 @default.
• W2970959547 cites W2171297959 @default.
• W2970959547 cites W2204091436 @default.
• W2970959547 cites W2336865896 @default.
• W2970959547 cites W2340084730 @default.
• W2970959547 cites W2473890466 @default.
• W2970959547 cites W2493507194 @default.
• W2970959547 cites W2559865294 @default.
• W2970959547 cites W2585771041 @default.
• W2970959547 cites W2592005401 @default.
• W2970959547 cites W2603317054 @default.
• W2970959547 cites W2749241774 @default.
• W2970959547 cites W2753413920 @default.
• W2970959547 cites W2791302651 @default.
• W2970959547 cites W2896426218 @default.
• W2970959547 cites W2902712114 @default.
• W2970959547 cites W4250178961 @default.
• W2970959547 doi "https://doi.org/10.3389/fmicb.2019.02148" @default.
• W2970959547 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6759608" @default.
• W2970959547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31620105" @default.
• W2970959547 hasPublicationYear "2019" @default.
• W2970959547 type Work @default.
• W2970959547 sameAs 2970959547 @default.
• W2970959547 citedByCount "7" @default.
• W2970959547 countsByYear W29709595472020 @default.
• W2970959547 countsByYear W29709595472022 @default.
• W2970959547 countsByYear W29709595472023 @default.
• W2970959547 crossrefType "journal-article" @default.
• W2970959547 hasAuthorship W2970959547A5013580236 @default.
• W2970959547 hasAuthorship W2970959547A5041661834 @default.
• W2970959547 hasAuthorship W2970959547A5042940760 @default.
• W2970959547 hasAuthorship W2970959547A5043555116 @default.
• W2970959547 hasAuthorship W2970959547A5073933688 @default.
• W2970959547 hasAuthorship W2970959547A5085316302 @default.
• W2970959547 hasBestOaLocation W29709595471 @default.
• W2970959547 hasConcept C118552586 @default.
• W2970959547 hasConcept C159047783 @default.
• W2970959547 hasConcept C159654299 @default.
• W2970959547 hasConcept C164027704 @default.
• W2970959547 hasConcept C179464577 @default.
• W2970959547 hasConcept C17991360 @default.
• W2970959547 hasConcept C203014093 @default.
• W2970959547 hasConcept C2776090121 @default.
• W2970959547 hasConcept C2776194053 @default.
• W2970959547 hasConcept C2776392238 @default.
• W2970959547 hasConcept C2776914184 @default.
• W2970959547 hasConcept C2777138892 @default.
• W2970959547 hasConcept C2777604421 @default.
• W2970959547 hasConcept C2778461978 @default.
• W2970959547 hasConcept C2778690821 @default.
• W2970959547 hasConcept C2780775167 @default.
• W2970959547 hasConcept C71924100 @default.
• W2970959547 hasConcept C8891405 @default.
• W2970959547 hasConceptScore W2970959547C118552586 @default.
• W2970959547 hasConceptScore W2970959547C159047783 @default.
• W2970959547 hasConceptScore W2970959547C159654299 @default.
• W2970959547 hasConceptScore W2970959547C164027704 @default.
• W2970959547 hasConceptScore W2970959547C179464577 @default.
• W2970959547 hasConceptScore W2970959547C17991360 @default.
• W2970959547 hasConceptScore W2970959547C203014093 @default.
• W2970959547 hasConceptScore W2970959547C2776090121 @default.
• W2970959547 hasConceptScore W2970959547C2776194053 @default.

• next